Subtopic Deep Dive

Eculizumab Therapy in Complement Disorders
Research Guide

What is Eculizumab Therapy in Complement Disorders?

Eculizumab therapy uses the monoclonal antibody eculizumab to inhibit C5 complement protein, treating disorders like paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG).

Eculizumab blocks terminal complement activation, preventing C5 convertase-mediated cleavage and membrane attack complex formation (Legendre et al., 2013; 1521 citations). Clinical trials showed it halts thrombotic microangiopathy in aHUS with renal function improvements. Over 50 papers document its use in complement-driven diseases.

Curated Papers

Key Challenges

Why It Matters

Eculizumab provides life-saving treatment for PNH and aHUS patients by inhibiting uncontrolled complement activation, reducing hemolysis and thrombosis (Legendre et al., 2013). It established C5 inhibition as a therapeutic class, enabling long-term disease control in rare disorders previously lacking options (Loirat and Frémeaux-Bacchi, 2011). Real-world applications include preventing dialysis in aHUS and improving quality of life in gMG, with ongoing studies exploring resistance mechanisms.

Key Research Challenges

Eculizumab Resistance Mechanisms

Some aHUS patients develop resistance due to mutations altering C5 binding or alternative pathway persistence (Legendre et al., 2013). This limits long-term efficacy. Research identifies neoepitope formation as a key factor.

Long-term Renal Outcomes

Renal recovery varies with treatment duration and initial damage in aHUS (Loirat and Frémeaux-Bacchi, 2011). Dialysis dependency persists in 30-50% of cases. Monitoring complement dysregulation is essential.

Infection Risk Management

C5 inhibition increases meningococcal infection susceptibility, requiring vaccination (Sarma and Ward, 2010). Balancing immunosuppression with therapy efficacy challenges clinical protocols. Over 20 case reports highlight breakthrough infections.

Essential Papers

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Cynthia M. Magro, J. Justin Mulvey, David Berlin et al. · 2020 · Translational research · 2.2K citations

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

Christophe Legendre, Christoph Licht, Petra Muus et al. · 2013 · New England Journal of Medicine · 1.5K citations

Eculizumab inhibited complement-mediated thrombotic microangiopathy and was associated with significant time-dependent improvement in renal function in patients with atypical hemolytic-uremic syndr...

Complement System Part I â€“ Molecular Mechanisms of Activation and Regulation

Nicolas S. Merle, S. Church, Véronique Frémeaux‐Bacchi et al. · 2015 · Frontiers in Immunology · 1.5K citations

Complement is a complex innate immune surveillance system, playing a key role in defense against pathogens and in host homeostasis. The complement system is initiated by conformational changes in r...

Complement System Part II: Role in Immunity

Nicolas S. Merle, Rémi Noé, Lise Halbwachs‐Mecarelli et al. · 2015 · Frontiers in Immunology · 988 citations

International audience

The complement system

J. Vidya Sarma, Peter A. Ward · 2010 · Cell and Tissue Research · 952 citations

Atypical hemolytic uremic syndrome

Chantal Loirat, Véronique Frémeaux‐Bacchi · 2011 · Orphanet Journal of Rare Diseases · 648 citations

C3 glomerulopathy: consensus report

Matthew C. Pickering, Vivette D. D’Agati, Carla Nester et al. · 2013 · Kidney International · 619 citations

Reading Guide

Foundational Papers

Start with Legendre et al. (2013) for clinical trial evidence in aHUS; Sarma and Ward (2010) for complement overview; Loirat and Frémeaux-Bacchi (2011) for aHUS genetics.

Recent Advances

Merle et al. (2015, Frontiers in Immunology, Parts I/II) on activation mechanisms; Morgan and Harris (2015) on therapeutic targeting.

Core Methods

C5 inhibition assays, CH50 measurements, eGFR tracking, and flow cytometry for PNH clones; trial endpoints include TMA event-free status (Legendre et al., 2013).

How PapersFlow Helps You Research Eculizumab Therapy in Complement Disorders

Discover & Search

Research Agent uses searchPapers and citationGraph on 'Eculizumab aHUS Legendre 2013' to map 1500+ citing papers, revealing resistance studies. exaSearch uncovers related trials; findSimilarPapers links to Pickering et al. (2013) on C3 glomerulopathy.

Analyze & Verify

Analysis Agent applies readPaperContent to Legendre et al. (2013), then verifyResponse with CoVe for claims on renal improvement. runPythonAnalysis extracts survival curves via pandas for statistical verification; GRADE grades evidence as high for aHUS efficacy.

Synthesize & Write

Synthesis Agent detects gaps in resistance mechanisms across Legendre (2013) and Loirat (2011), flagging contradictions. Writing Agent uses latexEditText, latexSyncCitations, and latexCompile for review manuscripts; exportMermaid diagrams complement pathways.

Use Cases

"Extract survival data from eculizumab aHUS trials and plot Kaplan-Meier curves."

Research Agent → searchPapers('eculizumab aHUS') → Analysis Agent → readPaperContent(Legendre 2013) → runPythonAnalysis(pandas/matplotlib plot) → researcher gets CSV-exported curves with p-values.

"Write LaTeX review on eculizumab resistance in PNH/aHUS."

Synthesis Agent → gap detection → Writing Agent → latexEditText(draft) → latexSyncCitations(Legendre 2013, Loirat 2011) → latexCompile → researcher gets PDF with figures.

"Find code for modeling complement inhibition kinetics."

Research Agent → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets runnable Python sims of C5 blockade from related Merle (2015) citations.

Automated Workflows

Deep Research workflow scans 50+ eculizumab papers via searchPapers → citationGraph → structured report with GRADE scores on outcomes. DeepScan applies 7-step CoVe to verify resistance claims from Legendre (2013). Theorizer generates hypotheses on next-gen inhibitors from pathway reviews (Merle et al., 2015).

Try Doxa for Eculizumab Therapy in Complement Disorders Research

Frequently Asked Questions

What is eculizumab?

Eculizumab is a monoclonal antibody inhibiting C5 complement cleavage, approved for PNH, aHUS, and gMG (Legendre et al., 2013).

What methods prove eculizumab efficacy?

Phase 3 trials measured thrombotic microangiopathy cessation and renal function via eGFR; Legendre et al. (2013) reported 80% improvement.

What are key papers?

Legendre et al. (2013, NEJM, 1521 citations) on aHUS; Loirat and Frémeaux-Bacchi (2011) on pathophysiology; Sarma and Ward (2010) on complement basics.